AgingResearch.NewsJoin free

Atrasentan

Atrasentan has been studied in 3 papers since 2026: 2 trials in people, 1 in animals; 3 in the past year. The newest story, Nov 1, 2026: “Urine proteins may aid drug monitoring in kidney disease”.

Intervention

3 papers study it7 findingsUpdated

PubChemChEBIMeSH

See all 3

“Six weeks of treatment with atrasentan resulted in a significant reduction in urinary clusterin excretion and an increase in sET-1 levels.”
Novel protein biomarkers for risk stratification and personalized medicineNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026doi:10.1093/ndt/gfag068

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

About aging: trials about aging, of every trial that tests the drug for any use.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 3 independent labs in 3 countries
  • 4 trials, none about aging
  • Funders: European Commission and 3 more
  • 6 of 7 findings with company ties
  • 4 of 4 trials sponsored by its developers
  • Human trial2
  • Animals1

Studies in people

2 studies gave atrasentan to people and measured what changed.

What did studies of Atrasentan find?

6

Studies of Atrasentan measured 6 outcomes; the most studied are urinary protein-to-creatinine ratio (1 study), hypertension (1) and eGFR (1).

Urinary protein-to-creatinine ratio

downin humans1

1 study

  1. Atrasentan decreases urinary protein-to-creatinine ratio in humans (added to background RASi and SGLT2i; versus placebo in a crossover design) (-25.3% (95% CI -36.8 to -11.7)).

    “Treatment with atrasentan versus placebo resulted in a difference in geometric mean percentage change in UPCR at week 12 of -25.3%”

    Human trialadded to background RASi and SGLT2i; versus placebo in a crossover design0.75 mg once daily12 weeksn = 54

    Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial

    Journal of the American Society of Nephrology : JASN

  2. Atrasentan decreases urinary protein-to-creatinine ratio in humans (-25.3% (95% CI, -36.8 to -11.7)).

    “Accordingly, the difference between atrasentan and placebo in the change from baseline in UPCR was −25.3% (95% CI, −36.8 to −11.7; P < 0.001).”

    Human trialtreatment period 1 was 12 weeks, and treatment period 2 was 24 weeksn = 54

    Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial

    Journal of the American Society of Nephrology : JASN

More on Urinary protein-to-creatinine ratio

Hypertension

downin mice1

1 study

  1. Atrasentan decreases hypertension in mice (high-fat diet-fed I-PpoI mice).

    “The selective ETAR antagonist atrasentan normalized blood pressure, reversed hepatic steatosis, restored high-density lipoprotein cholesterol, reduced visceral fat, and attenuated renal aging.”

    Animalshigh-fat diet-fed I-PpoI miceselective ETAR antagonist

    Endothelial DNA Damage Orchestrates Cardio-Kidney-Metabolic Dysfunction Through Endothelin-1 Signaling

    Arteriosclerosis, thrombosis, and vascular biology

More on Hypertension

eGFR

no changein humans1

1 study

  1. Atrasentan showed no clear effect on eGFR in humans (0.3 ml/min per 1.73 m2 (95% CI, -4.5 to 5.0)).

    “eGFR remained stable during 12 and 24 weeks of treatment with atrasentan and placebo throughout the study, regardless of treatment period (Figure and Supplemental Figure 1”

    Human trialtreatment period 1 was 12 weeks, and treatment period 2 was 24 weeksn = 52

    Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial

    Journal of the American Society of Nephrology : JASN

More on eGFR

Serum endothelin-1

upin humans1

1 study

  1. Atrasentan increases serum endothelin-1 in humans during the atrasentan enrichment phase of SONAR (+23.4% (95% CI 19.2-27.4)).

    “while serum ET-1 increased by 23.4% (95% CI 19.2-27.4)”

    Human trialduring the atrasentan enrichment phase of SONAR6 weeks

    Urine proteins may aid drug monitoring in kidney disease

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

More on Serum endothelin-1

Urinary clusterin-to-creatinine ratio

downin humans1

1 study

  1. Atrasentan decreases urinary clusterin-to-creatinine ratio in humans during the atrasentan enrichment phase of SONAR (-46.3% (95% CI -57.8 to -37.1)).

    “After 6 weeks of treatment with atrasentan, uCLU/Cr decreased by 46.3% (95% confidence interval [CI]: -57.8 to -37.1)”

    Human trialduring the atrasentan enrichment phase of SONAR6 weeks

    Urine proteins may aid drug monitoring in kidney disease

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

More on Urinary clusterin-to-creatinine ratio

uCLU/Cr

downin humans1

1 study

  1. Atrasentan decreases uCLU/Cr in humans (-46.3% (95% CI -57.8 to -37.1)).

    “Six weeks of treatment with atrasentan resulted in a significant reduction in urinary clusterin excretion and an increase in sET-1 levels.”

    Human trialn = 308

    Urine proteins may aid drug monitoring in kidney disease

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

More on uCLU/Cr

Who is developing Atrasentan?

1 company: Novartis Pharmaceuticals.

Companies
  • Novartis PharmaceuticalsPhase 3berger disease, bergers disease

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 2Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 03 papers in 12 months
Nephrology, Dialysis, Transplantation

Urine proteins may aid drug monitoring in kidney disease

A urine protein measure linked to kidney injury fell 46.3% from baseline after six weeks of atrasentan in people with chronic kidney disease.A urine protein measure linked to kidney injury fell 46.3% from baseline after six weeks of atrasentan in people with chronic kidney disease.

Randomized trial · 2,303 peopleBiomarkers
Paper

Related